Genentech, Tercica Prevail In Suit Against Insmed

Law360, New York (December 6, 2006, 12:00 AM EST) -- A California jury awarded $7.5 million plus royalties to biotechnology company Genentech Inc. and its licensee, Tercica Inc, after a “clean sweep” verdict that found a rival start-up infringed its patents for a drug used to treat hormone-deficiency in children, lawyers said Thursday.

After an 11-day trial and seven days of deliberations, the jury ordered defendant Insmed Inc. to pay the Silicon Valley partners 15% royalties on up to $100 million in sales of its Iplex drug for short stature, plus 20% royalties for sales beyond...
To view the full article, register now.